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1.0. considerations on an International standard for the one-Stage
Frothrombin Time in the Control of Anticoagulant Therapy
E. A. Lonucan and H. C. Hnuren
on the basis of the work of one of us (H. c. H.) on coagulation factor kinetics
and our experience at the Thrombosis Service, the following remarks are offered
as a contribution to the Subcommittee's considerations.
Let me begin by discussing the work done by Dr. Biggs and Dr. Denson. As
a primary basis for the standardization of the one-stage pro,thrombin time they
took the obvious rectilinearity of the curve of correladon between the clotting
time (or clotting ratio) and the reciprocal of concenrrarion (i.e., the dilution)
of normal plasma (1, 2). This rectilinear correlation has been cor,firrnej
statistically by our results (3) and holds not only for the one-stage prothrombin
time, but for all the so-called extrinsic rest sysrems, irrespective of whether a
single coagulation factor or the factor II, vII, and X.o-pl.* is tested (3,7,g).
For Thrornbotest (which measures the complex II, VII, and X), for instance, the
curved co{relation line given by the manufacrurer on double logarithmic paper
is perfectly rectilinear whdn presented as the aforemen,tioned correlation (Hig. 1).
In this telt, factor X appears to be rate-limiting as long as the three factors
are lowered to a similar degree (3).
o
d
3 zoo
c;
" ' f O Oo
c
o R n
-=
Fl rn
O 1 5 6 . 7  1 0  2 0
Thrombotest oct ivi ty(%, log,scote)
1 s 6.7 10 20 100
Thrombotest oct ivi ty (%)
Fig. 1. Correlation between clotting time (t) and concentration of normal plasma (c) as obtained
with the original Thrombotest. - The curve at the left gives the plot of log t against log c, that
at the right the correlation of t agaiist the inverse of c.
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The second basic concept taken foi the standardization put forward by Biggs
and Denson is the assumption that dilution of coagulation factors in whole
plasma from patients treated with vitamin K antagonists will also be rectilinear
in -the same kind of graph. This assumption' according to the authors, is
supported by the observation that in patients treated with coumarin congeners
the correlation between the clotting time ratios found with different methods
is rectilinear when plotted against each other. \ffe do not think that this argument
is valid. A rectilinear correlation curve between clotting times found with two
different thromboplastin reagents in coumarin plasmas containing varying
amounts of clotting factors tells us nothing except that the underlying time/
concentration curye displays the same shape. It gives us no information at all
about the shape itself, particularly with respect to rectilinearity'
Nevertheless, we afe of the opinion that Biggs' and Denson's assumption
is valid. Not only have we confirmed the rectilinear correlation between
clotting time ratios demonstrated by these authors, but we also have two sets
ol data that provide substantial evidence for the correctness of their assumPtion:
first, dilg,tion of normal plasma in the presence of plasma from a cotrmarin-
treated patient results in a rectilin e&r correlation between the coagulation time
ratio and the dilution (Fig. 2); second, and more important, the correlation
between Thrombotest coagulation times of blood of patients treated by our
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Fig. 2. Correlation between clotting time (t) and'coagulation factor concentration (c) as obtained
in absence and in presence of a fixed amount of plasma from a patient treated vrith a coumarin
congener (so-called coumarin plasma). - The concentration range of the factors II' VII, IX,
and-X was prepared by mixing normal plasma with A1(OH)r-adsorbed plasma in varying pro-
portions. To each of these mixtures a 6xed amount of A1(OH)r-adsorbed normal plasma (o -
iower .orve), coumarin plasma (o - upper curve) or Al(OH)s-adsorbed coumarin plasma (A -
lower .lrrrre) was added. The ratio which is the independent variable of the x-axis was calculated
from the known concentration of the factors II, VII, IX, and X in normal plasma (1000/o),
Al(OH)r-adsorbed normal or coumarin plasma (00/o) and the coumarin plasma (50/o).
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thrombosis service on a long-term basis and the inverse of the actiyity of the
eoagulation factors present in the blood of these coumarin-treated patients (as
determined in plasma diluted 1./40 and 1/80) is probably rectilinear (Fig. 3).
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Fig. 3. Correlation between Thrombotest time (t) and coagulation factor concentration (c) as
assessed in patients treated at the Thrombosis Service. - Each dot represents the correlation
found in an individual patient under iong-term anticoagulant ,r.",rn*r. The regression line
through these points differs markedly from the regression line obtained tvith dilutions of normal
plasma, but appears to maintain its rectilinearity.
Fig. 3 shows, in addition to recdlinearity, that coagulation times found with
dilutions of normal plasma (Owren's standard reference curve) are mucl shorter
than thos,e found with patients' undiluted plasma containing the same amount
of coagulation factors as the respective dilutions of normal plasma. In other
words, coumarin treatment causes a relative prolongation of the coagulation
time at the same level of coagulatio'n factors.
As far as we can see at the moment, the difference between the curves found
in patients and for dilutions of normal plasma is caused by a competitive
inhibitor of factor X. This inhibitor is probably a metabolic precursor of
factor X, released into the blood-stream in cases of vitamin K deficiency. The
inhib,itor was initially called preprothrombin (7) and has recently been
denominated in a more general wdy as PIVKA (Proteih lnduced by Vitamin K
lbsence or Antagonist$ (8).
The amount of the competitive inhibitor circulating in patients with different
levels of anticoagulation is, as a rule, independent of this level and sbatters
around a constant mean for all patients. As an inhibitor of the competitive type,
it causes only a difference in the steepness of the correlation curve and not a
deviation from rectilinearity. Hence, for Thrombotest, rhe real percenrage of
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coagulation factors present in a given patient's plasma can be calculated by
multiplying Thrombotest percentages by a constant (approx. 2.0).
The PlVKA-sensitivity of the test system is, according to our experience, one
of the reasons for differences in prolongation ratios; the Thrombotest, perhaps
because of the relatively low dilution of the patient's plasma (ro'ughly 1/10),
is particularly sensitive to PIVKA. Species specificity of the thrornboplastin
reagent is another reason for differences.
It should be kept in mind that all these considerations refer to blood or plasma
of patients kept in a steady state of anticoagulation in which the activity of
the four factors of the prothrombin complex is lowered to a similar degree
(4, 5). Rather serious complications arise in the initial phase of anticoagulant
treatment, when the activity of factor VII is often much lower than that of
factor X (and the other two factors of the prothrombin complex). This is illu-
strated by Fig. 3 of Biggs' paper (2), where deviations from the straight
regression line on the side of the larger ratio are obvious (long coagulation
times are seen mostly in patients in the initial phase of treatment or in cases
of acute change of tolerance).
To summarize our theoretical considerations concerning standardization of
the one-stage prothrombin time for the control of anticoagulation therapy:
evidence put forward by us supports the correctness of the conclusion reached
by Biggs and Denson. Hence, the calibration table presented by these authors
provides a unique key to the comparability of results obtained with different
thromboplastin reagents, at least as far as patients under steady-state anti-
coagulation are concerned.
For practical purposes, however, besides the introduction of a reference
preparation and a calibration table, the proposal made by Poller, namely the
introduction of a reagent to be used in a wide area, should also be seriously
considered. In the Netherlands, in spite of many prejudices, the Scientific
Committee of the Thrombosis Services of the Netherlands Red Cross already
proposed the use of Thrombotest 6 years ago, because of its outstanding quality
control by the manufactures and the fact that it can be obtained all over the
world. This year, about 75,OOO Dutch patients have been checked with Thrornbo-
test, 3,500 of these belonging to ouf Thrombosis Service. There have been almost
no complaints concerning the reagent.
' 
Differences between bptches are so small that in practice we use coagulation
times only for the adjustment of the dosage. Sensitivity to the initial factor VII
decrease is an important advantage of Thrombotest. Moreover, Thrombotest has
proven to be useful in assessing and irrefutably defining the intensity of treat-
menr during clinical trials. In two Dutch studies on the value of long-term
anticoagr-rlant rreatment in patients suffering from coronary thrombosis, both of
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which gave results favoring long-term anticoagulation treatment, the range of 
Thrombotest values aimed at was between 5% and 13% (10). 
As a concluding remark I may add that in discu ssing the introduction of 
an international standard, the questions of the quality control of the ultimate 
reference preparation and of coping with all the problems ari sing in the hundreds 
of laboratories using the standard should not be underestimated . 
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whidr gave results favoring long-term anticoagulation treatment, the range of
Thrombotesr values aimed ar was between 50lo and 130/o (10).
As a concluding remark r may add that in discussing the introduction of
an international standard, the'questions of the quality controi of the ultimate
reference preparution and of coping with all the problems arising in the hundreds
of laboratories using the standard should not be underestimated.
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